Jan Theys

ORCID: 0000-0002-9718-8251
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Virus-based gene therapy research
  • Nanoplatforms for cancer theranostics
  • Glioma Diagnosis and Treatment
  • Bacteriophages and microbial interactions
  • Cancer Cells and Metastasis
  • Epigenetics and DNA Methylation
  • Medical Imaging Techniques and Applications
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Nutrition and Health in Aging
  • Clostridium difficile and Clostridium perfringens research
  • Liver Disease Diagnosis and Treatment
  • Muscle Physiology and Disorders
  • Radiomics and Machine Learning in Medical Imaging
  • 3D Printing in Biomedical Research
  • Lipid metabolism and disorders
  • Biomedical and Engineering Education
  • RNA modifications and cancer
  • DNA Repair Mechanisms
  • Advanced Radiotherapy Techniques
  • Ubiquitin and proteasome pathways
  • GDF15 and Related Biomarkers
  • CRISPR and Genetic Engineering

Maastricht University
2016-2025

Maastricht University Medical Centre
2011-2021

Vanderbilt University
2019

Agostino Gemelli University Polyclinic
2019

The Barbara Ann Karmanos Cancer Institute
2019

Wayne State University
2019

Amsterdam UMC Location University of Amsterdam
2019

Erasmus MC
2019

Università Cattolica del Sacro Cuore
2019

Maastro Clinic
2007-2018

Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of tumors, which an important cause treatment resistance conventional therapies. Despite promising preclinical and clinical phase I II results, most described in this review, implementation hypoxia-activated clinic has, so far, not been successful. The lack stratification patients based on tumor hypoxia status, can vary widely, is sufficient account for failure III trials. To fully exploit potential...

10.1016/j.ctro.2019.01.005 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2019-01-18

The unique properties of the tumour microenvironment can be exploited by using recombinant anaerobic clostridial spores as highly selective gene delivery vectors. Although several Clostridium species have been generated during past decade, their efficacy has limited. Our goal was to substantially improve prospects clostridia a vector. Therefore, we assessed series nitroreductase (NTR) enzymes for capacity convert innocuous CB1954 prodrug its toxic derivative. Among tested, one showed...

10.1038/sj.bjc.6603367 article EN cc-by-nc-sa British Journal of Cancer 2006-10-03

Eukaryotic cells possess several mechanisms to protect the integrity of their DNA against damage. These include cell-cycle checkpoints, DNA-repair pathways, and also a distinct damage–tolerance system that allows recovery replication forks blocked at sites In both humans yeast, lesion bypass restart synthesis can occur through an error-prone pathway activated following mono-ubiquitination proliferating cell nuclear antigen (PCNA), protein found replication, recruitment specialized...

10.1371/journal.pgen.0020116 article EN cc-by PLoS Genetics 2006-07-17

In mammals, there are four NOTCH receptors and five Delta-Jagged-type ligands regulating many aspects of embryonic development adult tissue homeostasis. proteins type I transmembrane that interact with on adjacent cells activated by regulated intramembrane proteolysis (RIP). The activation mechanism NOTCH1 upon ligand binding is well understood requires cleavage ADAM10 metalloproteases prior to intramembranous γ-secretase. How the other human receptor homologues not known. Here, we dissect...

10.1128/mcb.00206-14 article EN Molecular and Cellular Biology 2014-05-20

// John T. Heap 1,5,* , Jan Theys 2,* Muhammad Ehsaan 1 Aleksandra M Kubiak Ludwig Dubois 2 Kim Paesmans Lieve Van Mellaert 3 Richard Knox 4 Sarah A. Kuehne Phillipe Lambin and Nigel P. Minton Clostridia Research Group, Centre for Biomolecular Sciences, School of Life The University Nottingham, Park, UK. Maastro Lab, Institute GROW, Maastricht, MD Netherlands. Molecular Bacteriology, Rega Medical Research, Leuven, Minderbroedersstraat,Belgium. Morvus Technology Limited, Ty Myddfai,...

10.18632/oncotarget.1761 article EN Oncotarget 2014-01-12

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. The current standard of care includes surgery followed by radiotherapy (RT) and chemotherapy with temozolomide (TMZ). Treatment often fails due to radiation resistance intrinsic or acquired TMZ a small percentage cells stem cell-like behavior (CSC). NOTCH signaling pathway expressed active human glioblastoma inhibitors attenuate growth vivo xenograft models. Here we show using an image guided micro-CT precision...

10.18632/oncotarget.9275 article EN Oncotarget 2016-05-10

Necrosis is a common feature of solid tumours that offers unique opportunity for targeted cancer therapy as it absent from normal healthy tissues. Tumour necrosis provides an ideal environment germination the anaerobic bacterium Clostridium endospores, resulting in tumour-specific colonisation. Two main species, novyi-NT and sporogenes, are at forefront this therapy, showing promise preclinical models. However, anti-tumour activity modest when used single agent, encouraging development...

10.1007/s40291-024-00695-0 article EN cc-by-nc Molecular Diagnosis & Therapy 2024-02-02

Abstract Background Cachexia, highly prevalent in patients with non‐small cell lung cancer (NSCLC), impairs quality of life and is associated reduced tolerance responsiveness to therapy decreased survival. MicroRNAs (miRNAs) are small non‐coding RNAs that play a central role post‐transcriptional gene regulation. Changes intramuscular levels miRNAs have been implicated muscle wasting conditions. Here, we aimed identify differentially expressed skeletal cachectic increase our understanding...

10.1002/jcsm.12512 article EN cc-by Journal of Cachexia Sarcopenia and Muscle 2019-12-11

Abstract Introduction Cancer cachexia, highly prevalent in lung cancer, is a debilitating syndrome characterized by involuntary loss of skeletal muscle mass and associated with poor clinical outcome, decreased survival negative impact on tumour therapy. Various tumour‐bearing animal models have been used to explore underlying mechanisms cancer cachexia. However, these do not simulate anatomical immunological features key wasting. Overcoming shortcomings essential translate experimental...

10.1002/jcsm.13222 article EN cc-by-nc-nd Journal of Cachexia Sarcopenia and Muscle 2023-04-06

ABSTRACT Hepatocellular carcinoma (HCC) is a major cause of cancer‐related deaths worldwide. Therapeutic options are limited, and therefore new therapeutic targets needed. Cathepsins, lysosomal proteases, implicated in various types cancer. While intracellular cathepsins have physiological functions, their extracellular secretion can lead to pathological effects. Cathepsin B (CTSB) stays active at neutral pH contributes several liver pathologies, including HCC. However, the mechanisms by...

10.1002/lci2.70016 article EN cc-by Liver international communications. 2025-03-01

AbstractTo increase the potential of attenuated Salmonella as gene delivery vectors for cancer treatment, we developed a hypoxia-inducible promoter system to limit expression specifically tumor. This approach is envisaged not only tumor specificity, but also target those cells that are most resistant conventional therapies. We demonstrate exponential growth bacteria identical under normoxia and hypoxia. A (HIP-1) was created from portion endogenous pepT shown drive reporter both acute...

10.4161/cbt.5.9.2951 article EN Cancer Biology & Therapy 2006-09-01

The search for effective means of selectively delivering high therapeutic doses anti-cancer agents to tumors has explored a variety systems in the last decade. ability intravenously injected clostridial spores infiltrate and thence germinate hypoxic regions solid is exquisitely specific, making this system an interesting addition therapy arsenal. To increase number proteins potentially useful cancer treatment we have tested possibility Clostridium acetobutylicum secrete rat interleukin-2...

10.1016/j.femsle.2005.03.037 article EN FEMS Microbiology Letters 2005-04-02
Coming Soon ...